Dysuria

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer

Retrieved on: 
Friday, January 12, 2024
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Histopathology, Weight loss, Gynaecology, Bevacizumab, Cisplatin, Hypothyroidism, University, Cancer, Risk, COVID-19, Diarrhea, Hyperthyroidism, Brachytherapy, Neoplasm, Perforated ulcer, Hepatitis, FIGO, CRT, Pyelonephritis, Colitis, Vagina, ClinicalTrials.gov, PD-L1, RECIST, Disease, Patient, Fever, CPS, Chemoradiotherapy, Vomiting, MRK, Death, Nephritis, Progression-free survival, OS, Radiation, Anemia, Survival, EBRT, Abdominal pain, Intraparenchymal hemorrhage, Uterus, Cervical cancer, Constipation, PFS, Fatal, Obstetrics, Hematopoietic stem cell transplantation, Pneumonitis, Nausea, Pelvic pain, Dysuria, Fatigue, GOG, Arm, Rash, Food, Merck & Co., Sepsis, Toxicity, News, Urinary tract infection, Appetite, Pharmaceutical industry

Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.

Key Points: 
  • Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.
  • “Building on the established role of KEYTRUDA in advanced cervical cancer, KEYTRUDA plus chemoradiotherapy is now the first anti-PD-1-based regimen approved in the U.S. for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer regardless of PD-L1 expression,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories.
  • The trial enrolled 1,060 patients with cervical cancer who had not previously received any definitive surgery, radiation, or systemic therapy for cervical cancer.
  • In the exploratory subgroup analysis of 596 patients with FIGO 2014 Stage III-IVA disease, 61 patients (21%) in the KEYTRUDA plus CRT arm (n=293) experienced a PFS event versus 94 patients (31%) in the placebo plus CRT arm (n=303).

Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer

Retrieved on: 
Wednesday, February 15, 2023
Biotechnology, Pharmaceutical, Health, Oncology, TURBT, Fatigue, ATLAS, American Urological Association, Aes, Dysuria, Patient, Cancer, AE, Bladder cancer, Mitomycins, Urology, Chairperson, Biopsy, Disease, Nursing, Pharmaceutical industry

Six patients completed treatment (6 doses), and 2 patients discontinued the study (5 doses and 4 doses, respectively) due to adverse events (AEs) unrelated to treatment.

Key Points: 
  • Six patients completed treatment (6 doses), and 2 patients discontinued the study (5 doses and 4 doses, respectively) due to adverse events (AEs) unrelated to treatment.
  • All 8 patients were evaluable for treatment response, and 6 of 8 (75%) achieved a complete response 3 months after starting treatment.
  • Home instillation was reported as feasible for visiting nurses, and 3 of 4 investigators considered at-home treatment “not different” than in-office treatment.
  • Patients were followed for AEs and treatment response was evaluated by visual observation, for cause biopsy, and urine cytology 3 months after treatment initiation.

Teleflex Celebrates 400,000 Patients Treated With the Minimally Invasive UroLift® System

Retrieved on: 
Thursday, December 15, 2022
Prostate, Hematuria, BPH, Bleeding, Quality of life, Annual report, Emergency medicine, NYSE, Health, Security (finance), Radiology, Heat, Anesthesia, Urology, American Urological Association, National Association Medical Staff Services, TFX, Pelvic pain, European Association of Urology, Infection, System 1, Teleflex, Patient, Medical imaging, Dysuria

“At Teleflex, we are honored to play an important role in enhancing the quality of life of hundreds of thousands of men with BPH.”

Key Points: 
  • “At Teleflex, we are honored to play an important role in enhancing the quality of life of hundreds of thousands of men with BPH.”
    The UroLift® System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).
  • More than 400,000 men have been treated with the UroLift® System in select markets worldwide.1
    Learn more at UroLift.com .
  • Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives.
  • We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers.

Published Data Demonstrate Consistent PUL Outcomes for the Treatment of Median Lobe Obstruction Across Controlled and Real-World Settings

Retrieved on: 
Tuesday, October 25, 2022
Pelvic pain, Prostatic urethral lift, Bleeding, General manager, Infection, Clinical trial, Anesthesia, Paper, NYSE, Patient, Patient satisfaction, BPH, IPSS, American Urological Association, Emergency medicine, Â, Solution, PUL, Prostate, Radiology, Teleflex, Health, Hematuria, Association, TURP, Safety, GLOBE, European Association of Urology, Heat, FDA, IDE, TFX, Pharmaceutical industry, Medical imaging, Health insurance, Dysuria, Urology, Man

WAYNE, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, announced today new data published in the peer-reviewed Journal of Endourology demonstrate the minimally invasive Prostatic Urethral Lift (PUL) procedure using the UroLift® System yields consistent safety, effectiveness and patient experience outcomes for benign prostatic hyperplasia (BPH) with and without obstructive median lobes.

Key Points: 
  • Ejaculatory function scores for men treated with the UroLift System were also significantly better than TURP at all timepoints.
  • PUL for obstructive median lobes in a real-world setting confirms controlled clinical trial results following treatment with the UroLift System.
  • Symptom and uroflow outcomes were largely consistent for obstructive median lobe patients treated in controlled and real-world settings; however, patients treated in a real-world setting experienced fewer post-operative catheterizations without elevated adverse events.
  • Furthermore, real-world safety, symptom and patient experience outcomes were equivalent between men with lateral and median lobe obstruction.

Innocoll and DURECT Announce U.S. launch of POSIMIR®

Retrieved on: 
Monday, September 26, 2022
Central nervous system, Injection, Safety, Bradycardia, Achievement, Patient, U.S. Securities and Exchange Commission, Bupivacaine, Technology, C-reactive protein, Pain management, Annual report, Headache, AH, Risk, Fatty liver disease, COVID-19, Respiratory arrest, Methemoglobinemia, Sale, Food, Diarrhea, Vomiting, Anesthetic, Bruise, Surgeon, DNA, Nausea, SEC, Patent, Dizziness, Allergy, Coma, FDA, NASH, Association, Shoulder joint, Tinnitus, Paresthesia, Form 10-K, Chondrolysis, United States patent law, Somnolence, SABER, Constipation, Marketing, Itch, Blood, Incidence, Hypersensitivity, Elective surgery, Private Securities Litigation Reform Act, Regulation of tobacco by the U.S. Food and Drug Administration, Chronic liver disease, CNS, Anemia, Dentistry, Pharmaceutical industry, Vaccine, Fever, Dysuria, Dysgeusia, Hypoesthesia

"We are excited to bring a potential cornerstone of multi-modal post-operative pain management to surgeons with the launch of POSIMIR," said Louis Pascarella, Chief Executive Officer of Innocoll.

Key Points: 
  • "We are excited to bring a potential cornerstone of multi-modal post-operative pain management to surgeons with the launch of POSIMIR," said Louis Pascarella, Chief Executive Officer of Innocoll.
  • Per the terms of the collaboration between Innocoll and DURECT, Innocoll will make a $2 million payment to DURECT triggered by the first commercial sale of POSIMIR.
  • Previously, in August 2022, DURECT was issued a new patent by the US Patent Office, extending US patent coverage of POSIMIR to at least 2041, resulting in an $8 million milestone payment by Innocoll to DURECT.
  • NOTE: POSIMIR is a trademark of Innocoll Pharmaceuticals Limited in the U.S. and a trademark of DURECT Corporation outside of the U.S. SABER is a trademark of DURECT Corporation.

Teleflex Announces Collaboration with FundamentalVR, to Improve Training Through Virtual Reality Simulation

Retrieved on: 
Thursday, August 25, 2022
Patient, NYSE, VR, Heat, Emergency medicine, Dysuria, Fundamental, Time, Pelvic pain, Urology, Solution, European Association of Urology, Man, American Urological Association, TFX, Infection, Learning, Radiology, Extended reality, BPH, GLOBE, Surgeon, Compliance, Anesthesia, Hematuria, Bleeding, Prostate, Association, Virtual reality, AUA, Health, General manager, Adoption, Video game console, Medical imaging, Teleflex

WAYNE, Pa., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced a new agreement with FundamentalVR, a world leader in virtual reality (VR) integration for medical simulation. The agreement will provide Teleflex with a VR training platform to accelerate the effective use of the company’s UroLift® 2 System, an innovative technology for treatment of benign prostatic hyperplasia (BPH), commonly known as enlarged prostate. The VR training platform integrates tactile feedback and a digital representation of the UroLift® 2 System to provide urologists with a “hands-on” VR experience that can accelerate their learning.

Key Points: 
  • The customized solution from FundamentalVR will enable urologists globally to practice the procedure remotely in a virtual environment.
  • Teleflex showcased the Fundamental Surgery platform at the companys UroLift System booth at the 2022 American Urological Association (AUA) meeting in New Orleans.
  • Teleflex is a global provider of medical technologies designed to improve the health and quality of peoples lives.
  • This enables medical devices and procedures to drive consistency and compliance across their training programs, provided on their multimodal Fundamental Surgery platform.

Teleflex Announces Pocono Raceway NASCAR Event to Raise Visibility of Enlarged Prostate and the Importance of Regular Health Screenings

Retrieved on: 
Thursday, July 21, 2022
Association, Anesthesia, Infection, Fan Fair, BPH, Detroit Triple Fan Fair, Urology, GLOBE, Awareness, Bleeding, NYSE, Ambassador, Urethra, Solution, Hematuria, Health, General manager, COVID-19, News, European Association of Urology, Patient, Heat, American Urological Association, Prostate, NASCAR, TFX, Teleflex, Pocono Raceway, Man, Radiology, Pelvic pain, Dysuria, Emergency medicine, Medical imaging, Pharmaceutical industry

BPH is a non-cancerous enlargement of the prostate that occurs naturally for some men as they age.

Key Points: 
  • BPH is a non-cancerous enlargement of the prostate that occurs naturally for some men as they age.
  • At the Pocono Raceway event, Teleflex will host a booth at the Fan Fair with educational activities and information on BPH.
  • NASCAR driver JJ Yeley, 45, will sign autographs in the UroLift System booth at times to be announced during the weekend.
  • Teleflex is the home of Arrow, Deknatel, LMA, Pilling, QuikClot, Rsch, UroLift, and Weck trusted brands united by a common sense of purpose.

New Data Reinforce Efficacy of the UroLift® System for the Treatment of Enlarged Prostate

Retrieved on: 
Friday, July 1, 2022
Patient, Research, Prostatic urethral lift, GLOBE, Consultant, U.S. Securities and Exchange Commission, BPH, Bleeding, Quality of life, LMA, Heat, Security (finance), European Association of Urology, TURP, Pelvic pain, De novo, Weck, Hematuria, Population, IPSS, American Urological Association, NYSE, Emergency medicine, Solution, Congress, Man, Infection, PUL, Anesthesia, University of Texas Southwestern Medical Center, Health, Radiology, Annual report, EAU, Association, Teaching hospital, TFX, University, Prostate, PVP, Safety, Conference, Medical imaging, Pharmaceutical industry, Urology, Dysuria, QuikClot, Teleflex

The data will be presented at the 37th Annual European Association of Urology (EAU) Congress in Amsterdam and virtually.

Key Points: 
  • The data will be presented at the 37th Annual European Association of Urology (EAU) Congress in Amsterdam and virtually.
  • Extensive research has shown that the UroLift System can consistently and rapidly improve BPH symptoms for our patients.
  • Medical Director, Urology Clinic, University Hospital, Freiburg.2
    The UroLift System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH).
  • The UroLift permanent implants, which can be delivered during an outpatient procedure, relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue.

Teleflex Celebrates June Men’s Health Month with Launch of UroLift® Patient Ambassador Program

Retrieved on: 
Wednesday, June 1, 2022
Infection, Time, Emergency medicine, Program, Radiology, Man, TFX, American Urological Association, Urology, Bleeding, Pelvic pain, System 1, Volunteering, Solution, Â, Physician, Heat, Prostate, BPH, Prostatic urethral lift, GLOBE, Patient, European Association of Urology, Health, NYSE, Sleep, Association, Hematuria, General manager, Anesthesia, Teleflex, Medical imaging, Health insurance, Dysuria

In celebrating Mens Health Month, we celebrate the 350,000 men who have taken charge of their health with the UroLift System.

Key Points: 
  • In celebrating Mens Health Month, we celebrate the 350,000 men who have taken charge of their health with the UroLift System.
  • We are also excited to launch the UroLift Patient Ambassador Program, an important resource for men considering this treatment for their BPH symptoms, said Kevin Hardage, President and General Manager, Teleflex Interventional Urology.
  • We encourage men considering this treatment option to reach out to an Ambassador to learn about their personal experiences.
  • The UroLift Patient Ambassador Program is designed to connect people who are exploring minimally invasive BPH treatment options with men who are available to share their personal experiences with the UroLift System procedure.

CG Oncology Presents New Clinical Data on Two Ongoing Programs at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Retrieved on: 
Saturday, June 4, 2022
Oncology, Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, MSD, CR, Hyperglycemia, Urinary bladder, AUA, Urine, Society, Hypothyroidism, AACR, Cystectomy, Toxicity, American Urological Association, BCG, ASCO, American Association for Cancer Research, Annual general meeting, H. Lee Moffitt Cancer Center & Research Institute, American Society of Clinical Oncology, Nocturia, American Association, Pembrolizumab, Patient, Merck Sharp & Dohme Federal Credit Union, Bladder cancer, Nivolumab, Twitter, MD, Population, Hematuria, Chills, Safety, Merck & Co., Pharmaceutical industry, Medical imaging, Vaccine, Fatigue, NMIBC, MIBC, Merck, Dysuria, Oncology, Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Biotechnology

CG Oncology, Inc. , a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for patients with advanced cancer, today announced interim data on two ongoing clinical studies will be presented at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

Key Points: 
  • CG Oncology, Inc. , a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for patients with advanced cancer, today announced interim data on two ongoing clinical studies will be presented at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.
  • As of the interim analysis, based on a data cutoff on May 13, 2022, 24 patients were evaluable for efficacy with a minimum of 3 months follow up.
  • CG Oncology is a clinical-stage biotechnology company focused on developing the next evolution of oncolytic immunotherapy for patients with advanced cancer.
  • At CG Oncology, we aim to take the next evolutionary step in delivering innovative cancer care to millions of patients in need worldwide.